参考文献/References:
[1]Cho NH,Shaw JE,Karuranga S,et al.IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045[J].Diabetes Res Clin Pract,2018,138:271-281.[2]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):315-409.[3]Zhou S,Zhang Z,Zhang Z,et al.Evaluation of left ventricular systolic and diastolic function in subjects with prediabetes and diabetes using cardiovascular magnetic resonance-feature tracking[J].Acta Diabetol,2022,59(4):491-499.[4]Liu Y,Ma J,Guo J,et al.Characteristics of Myocardial Perfusion in Type 2 Diabetes Mellitus and Its Association with Left Ventricular Diastolic Dysfunction: A Study of Myocardial Contrast Echocardiography[J].Int J Gen Med,2021,14:7533-7543.[5]Chee KH,Tan KL,Luqman I,et al.Prevalence and Predictors of Left Ventricular Diastolic Dysfunction in Malaysian Patients With Type 2 Diabetes Mellitus Without Prior Known Cardiovascular Disease[J].Front Cardiovasc Med,2021,8:676862.[6]Boonman-de Winter LJ,Rutten FH,Cramer MJ,et al.High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes[J].Diabetologia,2012,55(8):2154-2162.[7]Kozakova M,Morizzo C,Fraser AG,et al.Impact of glycemic control on aortic stiffness, left ventricular mass and diastolic longitudinal function in type 2 diabetes mellitus[J].Cardiovasc Diabetol,2017,16(1):78.[8]Skali H,Shah A,Gupta DK,et al.Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study[J].Circ Heart Fail,2015,8(3):448-454.[9]Halabi A,Sen J,Huynh Q,et al.Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis[J].Cardiovasc Diabetol,2020,19(1):124.[10]Andersson C,S?覬gaard P,Hoffmann S,et al.Metformin is associated with improved left ventricular diastolic function measured by tissue Doppler imaging in patients with diabetes[J].Eur J Endocrinol,2010,163(4):593-599.[11]Salvatore T,Galiero R,Caturano A,et al.Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence[J].Biomolecules,2021,11(12):11121834.[12]Wang MT,Huang YL,Lai JH,et al.Association Between Specificity of Sulfonylureas to Cardiac Mitochondrial KATP Channels and the Risk of Major Adverse Cardiovascular Events in Type 2 Diabetes[J].Diabetes Care,2022:1779.[13]Rosenstock J,Kahn SE,Johansen OE,et al.Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial[J].JAMA,2019,322(12):1155-1166.[14]Clarke GD,Solis-Herrera C,Molina-Wilkins M,et al.Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes[J].Diabetes Care,2017,40(11):1530-1536.[15]Nesti L,Tricò D,Mengozzi A,et al.Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug[J].Cardiovasc Diabetol,2021,20(1):109.[16]Yamada H,Tanaka A,Kusunose K,et al.Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study[J].Cardiovasc Diabetol,2017,16(1):63.[17]Zhang X,Zhang Z,Yang Y,et al.Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits[J].Cardiovasc Diabetol,2018,17(1):160.[18]Shi FH,Li H,Shen L,et al.Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function[J].J Clin Endocrinol Metab,2022,107(4):1191-1203.[19]Moellmann J,Klinkhammer BM,Droste P,et al.Empagliflozin improves left ventricular diastolic function of db/db mice[J].Biochim Biophys Acta Mol Basis Dis,2020,1866(8):165807.[20]Dyck JRB,Sossalla S,Hamdani N,et al.Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects[J].J Mol Cell Cardiol,2022,167:17-31.[21]Bizino MB,Jazet IM,Westenberg JJM,et al.Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial[J].Cardiovasc Diabetol,2019,18(1):55.[22]Withaar C,Meems LMG,Markousis-Mavrogenis G,et al.The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction[J].Cardiovasc Res,2021,117(9):2108-2124.[23]Konkwo C,Perry RJ.Imeglimin: Current Development and Future Potential in Type 2 Diabetes[J].Drugs,2021,81(2):185-190.[24]Kitakata H,Endo J,Hashimoto S,et al.Imeglimin prevents heart failure with preserved ejection fraction by recovering the impaired unfolded protein response in mice subjected to cardiometabolic stress[J].Biochem Biophys Res Commun,2021,572:185-190.[25]Kenchaiah S,Ding J,Carr JJ,et al.Pericardial Fat and the Risk of Heart Failure[J].J Am Coll Cardiol,2021,77(21):2638-2652.[26]于秀清,尹春风.卡维地洛治疗糖尿病性心肌病效果及对糖脂代谢的影响[J].中华保健医学杂志,2021(6):654-655.[27]Domagoj M,Branka JZ,Jelena M,et al.Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction - Results from the Croatian heart failure (CRO-HF) registry[J].Med Clin (Barc),2019,152(2):43-49.[28]Werida R,Khairat I,Khedr NF.Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia[J].Biomed Pharmacother,2021,135:111179.[29]Al-Rasheed NM,Al-Rasheed NM,Hasan IH,et al.Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats[J].Oxid Med Cell Longev,2017,2017:1092015.[30]Sukumaran V,Gurusamy N,Yalcin HC,et al.Understanding diabetes-induced cardiomyopathy from the perspective of renin angiotensin aldosterone system[J].Pflugers Arch,2022,474(1):63-81.[31]Aroor AR,Mummidi S,Lopez-Alvarenga JC,et al.Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness[J].Cardiovasc Diabetol,2021,20(1):80.[32]杨政,吴玉林.治疗急性脑梗死的新型脑保护药依达拉奉[J].中国新药杂志,2002(12):911-913.[33]Wang L,Zeng YQ,Gu JH,et al.Novel oral edaravone attenuates diastolic dysfunction of diabetic cardiomyopathy by activating the Nrf2 signaling pathway[J].Eur J Pharmacol,2022,920:174846.[34]尤良震,潘海娥,代倩倩,等.糖尿病心脏病中医病机述要[J].中医杂志,2021(12):1013-1019.[35]Zhang B,Zhang CY,Zhang XL,et al.Guan Xin Dan Shen formulation protects db/db mice against diabetic cardiomyopathy via activation of Nrf2 signaling[J].Mol Med Rep,2021,24(1):12170.[36]Yan M,Li L,Wang Q,et al.The Chinese herbal medicine Fufang Zhenzhu Tiaozhi protects against diabetic cardiomyopathy by alleviating cardiac lipotoxicity-induced oxidative stress and NLRP3-dependent inflammasome activation[J].Biomed Pharmacother,2022,148:112709.[37]Ebrahimi Mousavi S,Ghoreishy SM,Hemmati A,et al.Association between magnesium concentrations and prediabetes: a systematic review and meta-analysis[J].Sci Rep,2021,11(1):24388.[38]Liu M,Jeong EM,Liu H,et al.Magnesium supplementation improves diabetic mitochondrial and cardiac diastolic function[J].JCI Insight,2019,4(1):123182.[39]Wilson GA,Wilkins GT,Cotter JD,et al.HIIT Improves Left Ventricular Exercise Response in Adults with Type 2 Diabetes[J].Med Sci Sports Exerc,2019,51(6):1099-1105.[40]Otten J,Andersson J,St?覽hl J,et al.Exercise Training Adds Cardiometabolic Benefits of a Paleolithic Diet in Type 2 Diabetes Mellitus[J].J Am Heart Assoc,2019,8(2):e010634.[41]Marthi A,Donovan K,Haynes R,et al.Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis[J].J Am Soc Nephrol,2018,29(7):2015-2027.[42]S?覬rensen MH,Bojer AS,J?rgensen NR,et al.Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics[J].Cardiovasc Diabetol,2020,19(1):158.[43]Liu BL,Cheng M,Hu S,et al.Overexpression of miR-142-3p improves mitochondrial function in cardiac hypertrophy[J].Biomed Pharmacother,2018,108:1347-1356.[44]Yang P,Dong X,Zhang Y.MicroRNA profiles in plasma samples from young metabolically healthy obese patients and miRNA-21 are associated with diastolic dysfunction via TGF-β1/Smad pathway[J].J Clin Lab Anal,2020,34(6):e23246.[45]Fu J,Lin F,Pan Z,et al.Correlations of circulating miR-26b level with left ventricular hypertrophy and cardiac function in elderly patients with hypertension[J].Pak J Med Sci,2021,37(4):966-971.[46]Molvin J,Jujic A,Nilsson PM,et al.A diabetes-associated genetic variant is associated with diastolic dysfunction and cardiovascular disease[J].ESC Heart Fail,2020,7(1):348-356.[47]da Silva JS,Gon?觭alves RGJ,Vasques JF,et al.Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy[J].Cells,2022,11(2):11020240.[48]Van Linthout S,Hamdani N,Miteva K,et al.Placenta-Derived Adherent Stromal Cells Improve Diabetes Mellitus-Associated Left Ventricular Diastolic Performance[J].Stem Cells Transl Med,2017,6(12):2135-2145.
相似文献/References:
[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in
Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(09):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Journal of Medical Information,2018,31(09):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的
相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Journal of Medical Information,2018,31(09):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(09):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Journal of Medical Information,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]刘静波,黄 萍,赵 静.应用微信平台对初发中青年2型糖尿病患者进行
健康管理模式的研究[J].医学信息,2018,31(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Journal of Medical Information,2018,31(09):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
[7]丁 星,赵 畅,张海严,等.麦邦数据远程传输型血糖仪临床测量准确性的评价研究[J].医学信息,2018,31(15):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
DING Xing,ZHAO Chang,ZHANG Hai-yan,et al.Evaluation of Accuracy of Clinical Measurement of Maibang Remote Data Transmission Glucometer[J].Journal of Medical Information,2018,31(09):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
[8]梁延洋,程艳娜,华柏慧,等.胃癌合并2型糖尿病术后血糖改善的临床观察[J].医学信息,2018,31(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(09):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[9]刘小红.长效胰岛素联合口服降糖药治疗2型糖尿病的
疗效与安全性评价[J].医学信息,2018,31(18):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
LIU Xiao-hong.Efficacy and Safety of Long Acting Insulin Combined with Oral Hypoglycemic Agents in Treatment of Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(09):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
[10]鲍 哲,杨升伟,柯赛赛,等.益生元对2型糖尿病患者糖脂代谢的影响[J].医学信息,2018,31(18):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]
BAO Zhe,YANG Sheng-wei,KE Sai-sai,et al.Effect of Prebiotics on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes mellitus[J].Journal of Medical Information,2018,31(09):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]